The medical device industry's long-anticipated shift toward domestic manufacturing is finally materializing, but the transition is proving messier than many anticipated. What began as a post-pandemic discussion about supply chain resilience has evolved into concrete capital investments and production relocations—moves that are already creating significant ripple effects across healthcare delivery networks.
For years, reshoring remained largely theoretical. Device makers cited regulatory complexity, labor costs, and established overseas manufacturing ecosystems as barriers to bringing production back to American soil. The pandemic exposed the vulnerabilities of this calculus, forcing executives to reckon with geopolitical tensions, tariff uncertainties, and the reputational risks of supply chain disruptions. Now, many are moving forward with reshoring initiatives, but they're confronting a reality that strategic planning documents didn't fully anticipate: the domestic manufacturing infrastructure simply isn't ready to absorb this scale of production migration.
The Capacity Crunch
The most pressing challenge emerging from reshoring efforts centers on manufacturing capacity. The United States lacks sufficient facilities, specialized equipment, and trained workforce to immediately absorb the volume of device production that companies are attempting to bring onshore. This gap creates a transitional period where manufacturers must simultaneously operate legacy overseas facilities while building or retrofitting domestic ones—a capital-intensive, operationally complex undertaking that's already impacting timelines and costs.
For health system leaders, this capacity constraint translates into procurement uncertainties and potential supply disruptions during the transition period. Device manufacturers navigating reshoring may face production delays, quality control challenges as they establish new manufacturing processes, or pricing volatility as fixed costs are absorbed across smaller production volumes during ramp-up phases. These factors could complicate purchasing agreements and budgeting assumptions that health systems rely on for capital equipment planning.
Vendors, meanwhile, must balance shareholder expectations for cost efficiency with the substantial investments required to establish domestic manufacturing. This tension will likely manifest in vendor consolidation, selective reshoring of high-margin or strategic products, or partnerships with contract manufacturers who can absorb some capacity risk. Early movers in the reshoring space may gain competitive advantages through proximity to customers and improved supply chain responsiveness, but they'll also shoulder higher transition costs in the near term.
The workforce dimension adds another layer of complexity. Building a skilled manufacturing workforce in the United States requires training programs, competitive compensation, and geographic relocation of operations to regions with available labor. These expenses won't disappear; they'll simply shift from overseas labor arbitrage to domestic productivity and automation investments.
For health system procurement teams, the reshoring wave creates both risks and opportunities. In the near term, expect increased communication about product availability, potential price adjustments, and longer procurement lead times as manufacturers optimize their supply chains. Vendors transparent about their reshoring timelines and willing to work collaboratively on transition planning will likely strengthen customer relationships.
However, long-term benefits could be substantial. Reshoring promises improved supply chain visibility, shorter lead times for urgent orders, and reduced geopolitical risk exposure. Health systems that build strategic partnerships with vendors managing this transition thoughtfully may benefit from enhanced reliability and responsiveness once new manufacturing facilities reach full operational capacity.
The key for both health system leaders and vendors is recognizing that reshoring isn't a binary event but a multiyear transformation. Success requires flexibility, transparent communication, and willingness to absorb short-term friction for longer-term supply chain resilience.
Reporting basis: medtechdive.com. Analysis by the HTC editorial desk.